文献速递瓣膜病与结构性心脏病

经股动脉TAVI中球囊扩张与自膨胀瓣膜的临床结局比较:CENTER协作研究

Comparison of balloon-expandable vs. self-expandable valves in patients undergoing transfemoral transcatheter aortic valve implantation: from the CENTER-collaboration.
PubMed 文献 · Eur Heart J · 2019-01-01

该研究汇总10个注册研究或临床试验数据,经倾向性评分匹配比较经股动脉TAVI中球囊扩张瓣膜与自膨胀瓣膜的临床结局。30天随访显示两组死亡率无统计学差异,球囊扩张瓣膜组卒中及起搏器植入发生率更低,但新一代球囊扩张瓣膜组大出血或危及生命出血更常见。

要点

  • 经股动脉TAVI中,球囊扩张瓣膜组30天卒中发生率低于自膨胀瓣膜组
  • 球囊扩张瓣膜组需起搏器植入的风险约为自膨胀瓣膜组的三分之一
  • 新一代球囊扩张瓣膜组大出血或危及生命出血发生率高于新一代自膨胀瓣膜组

核心结论

  • 经股动脉TAVI中,球囊扩张瓣膜组30天卒中及起搏器植入发生率低于自膨胀瓣膜组,但新一代球囊扩张瓣膜组大出血或危及生命出血更常见,30天死亡率两组无统计学差异。

研究设计与样本

  • CENTER协作研究通过系统检索筛选10个注册研究或临床试验,汇总12 381例经股动脉TAVI患者数据,其中球囊扩张瓣膜组6239例、自膨胀瓣膜组6142例,采用倾向性评分方法减少治疗选择偏倚和混杂。

主要发现

  • 30天随访死亡率球囊扩张瓣膜组5.3% vs 自膨胀瓣膜组6.2%,RR 0.9(95%CI 0.7-1.0),P=0.10,无统计学差异。
  • 30天卒中发生率球囊扩张瓣膜组1.9% vs 自膨胀瓣膜组2.6%,RR 0.7(95%CI 0.5-1.0),P=0.03。
  • 起搏器植入率球囊扩张瓣膜组7.8% vs 自膨胀瓣膜组20.3%,RR 0.4(95%CI 0.3-0.4),P<0.001。
  • 新一代球囊扩张瓣膜组大出血或危及生命出血发生率4.8% vs 新一代自膨胀瓣膜组2.1%,RR 2.3(95%CI 1.6-3.3),P<0.001。

临床怎么用

  • 在经股动脉TAVI瓣膜选择时,可结合患者卒中风险、起搏器植入风险及出血风险,权衡球囊扩张瓣膜与自膨胀瓣膜的获益与风险。

局限性

  • 本研究为基于观察性数据的倾向性评分匹配分析,当前结果需在大规模随机对照试验中进一步证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this study was to compare clinical outcomes of patients undergoing transfemoral transcatheter aortic valve implantation (TAVI) with balloon-expandable (BE) valves vs. self-expandable (SE) valves. Transcatheter aortic valve implantation is a minimally invasive and lifesaving treatment in patients with aortic valve stenosis. Even though BE-valves and SE-valves are both commonly used on a large scale, adequately sized trials comparing clinical outcomes in patients with severe aortic valve stenosis treated with BE-valves compared with SE-valves are lacking. METHODS AND RESULTS: In this CENTER-collaboration, data from 10 registries or clinical trials, selected through a systematic search, were pooled and analysed. Propensity score methodology was used to reduce treatment selection bias and potential confounding. The primary endpoints were mortality and stroke at 30 days follow-up in patients treated with BE-valves compared with SE-valves. Secondary endpoints included clinical outcomes, e.g. bleeding during hospital admission. All outcomes were split for early-generation BE-valves compared with early-generation SE-valves and new-generation BE-valves with new-generation SE-valves. The overall patient population (N = 12 381) included 6239 patients undergoing TAVI with BE-valves and 6142 patients with SE-valves. The propensity matched population had a mean age of 81 ± 7 years and a median STS-PROM score or 6.5% [interquartile range (IQR) 4.0-13.0%]. At 30-day follow-up, the mortality rate was not statistically different in patients undergoing TAVI with BE-valves compared with SE-valves [BE: 5.3% vs. SE: 6.2%, relative risk (RR) 0.9; 95% confidence interval (CI) 0.7-1.0, P = 0.10]. Stroke occurred less frequently in patients treated with BE-valves (BE: 1.9% vs. SE: 2.6%, RR 0.7; 95% CI 0.5-1.0, P = 0.03). Also, patients treated with BE-valves had a three-fold lower risk of requiring pacemaker implantation (BE: 7.8% vs. SE: 20.3%, RR 0.4; 95% CI 0.3-0.4, P < 0.001). In contrast, patients treated with new-generation BE-valves more frequently experienced major and life-threatening bleedings compared with new-generation SE-valves (BE: 4.8% vs. SE: 2.1%, RR 2.3; 95% CI 1.6-3.3, P < 0.001). CONCLUSION: In this study, which is the largest study to compare valve types in TAVI, we demonstrated that the incidence of stroke and pacemaker implantation was lower in patients undergoing transfemoral TAVI with BE-valves compared with SE-valves. In contrast, patients treated with new-generation BE-valves more often suffered from major or life-threatening bleedings than patients with new-generation SE-valves. Mortality at 30-days was not statistically different in patients treated with BE-valves compared with SE-valves. This study was a propensity-matched analysis generated from observational data, accordingly current outcomes will have to be confirmed in a large scale randomized controlled trial.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Vlastra W, Chandrasekhar J, Muñoz-Garcia AJ, et al. Comparison of balloon-expandable vs. self-expandable valves in patients undergoing transfemoral transcatheter aortic valve implantation: from the CENTER-collaboration. Eur Heart J. 2019. PMID: 30590565. doi:10.1093/eurheartj/ehy805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。